Top Biotechs at ASCO: Ying Huang on Carvykti’s 5-Year Data and Expanding CAR-T Therapy in Myeloma

Описание: In this episode of Top Biotechs at ASCO, Ying Huang, CEO of Legend Biotech, a leader in cell therapy innovation. Ying shares exciting five-year data for Carvykti (cilta-cel), Legend’s CAR-T therapy for relapsed/refractory multiple myeloma, presented at ASCO 2025.

Legend’s latest results from the CAR-2.1 study show unprecedented outcomes:
✅ One-third of patients remain progression-free five years after a single infusion.
✅ Median overall survival extended to 60 months.
✅ Deep responses with MRD negativity in many patients.

#TopBiotechsAtASCO #LegendBiotech #Carvykti #MultipleMyeloma #CellTherapy #CAR_T #ASCO2025

SUBSCRIBE to get the latest #oncodaily    / @oncodailytv  

Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn:   / oncodaily  
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram:   / oncodailynews  
Follow OncoDaily on TikTok:   / oncodaily  
Like OncoDaily on Facebook:   / oncodaily  

SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter

About OncoDaily
OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information.

Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research.

🔔 New videos every day!
💻 Visit us at https://oncodaily.com/